PARP1 and neurodegenerative disease: Furthermore, the NAD+ precursor nicotinamide ribose and PARP inhibitors are proposed to combat cancer and a host of inflammatory and neurodegenerative diseases (Basello and Scovassi, 2015; Lee et al., 2015; Ohmoto and Yachida, 2017; Vaur et al., 2017).